"The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternat"...
The most frequently observed reactions include lightheadedness, dizziness, drowsiness, sedation, nausea, vomiting, constipation, pruritus, and skin reactions.
Read the Synalgos DC (aspirin, caffeine, and dihydrocodeine bitartrate capsules, usp) Side Effects Center for a complete guide to possible side effects
The CNS-depressant effects of Synalgos-DC may be additive with that of other CNS depressants. See “WARNINGS.” Aspirin may enhance the effects of anticoagulants and inhibit the uricosuric effects of uricosuric agents.
Clinical studies of Synalgos-DC did not include sufficient numbers of subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects.
In general, dose selection for an elderly patient should be cautious, starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Last reviewed on RxList: 6/4/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Synalgos DC Information
Report Problems to the Food and Drug Administration
Chronic Pain/Back Pain
Find tips and advances in treatment.